Imaging Could Improve Treatment of COPD Patients
“COPD is a very heterogeneous disease,” said study co-author Grace Parraga, PhD, from the Robarts Research Institute in London, Ontario, Canada. “Patients are classified based on spirometry, but patients with the same air flow may have different symptoms and significant variation in how much regular activity they can perform, such as walking to their car or up the stairs in their home.”
Spirometry is a lung function test — in which the patient takes a breath and exhales forcefully into a tube connected to a machine — that is commonly used to help diagnose COPD. This test produces a figure called the forced expiratory volume in one second (FEV1). According to researchers, FEV1 does not necessarily reflect the whole picture of the lungs, but airways disease and emphysema can be directly measured with imaging.
For the study, Dr. Parraga and colleagues performed conventional CT and inhaled noble gas MRI (a technique for visualising air spaces in the lungs) on 116 people with COPD, including 80 with milder disease. The patients also underwent lung capacity testing, filled out a quality of life questionnaire and took a six-minute walk to measure their exercise tolerance over a short period of time.
The researchers found that in mild-to-moderate COPD patients with modestly abnormal FEV1, MRI measurements of emphysema were strongly correlated with exercise limitation, while both CT and MRI measurements of emphysema helped explain symptoms.
The implications of the findings are significant for patients with mild COPD and abnormal FEV1, according to Dr. Parraga. “FEV1 doesn’t tell the whole story,” she noted. “With lung imaging, we can look at patients with mild disease much more carefully and change treatment if necessary.”
Findings associated with COPD include emphysema, or damage to the air sacs in the lungs that prevents people from getting the oxygen they need, especially during exercise. While no cure exists for emphysema, there are steps people can take to mitigate symptoms. Emphysema is under-recognised as a source of COPD, Dr. Parraga said, and as a result, patients may be getting suboptimal treatment.
Figure 1. Images in representative patients with mild-to-moderate or severe COPD.
Source and image credit: RSNA
Published on : Tue, 7 Jul 2015
A breakthrough in biopsy efficiency The Brevera system streamlines the entire breast biopsy process from start to finish – with real-time imaging for instant verification and automated post-biopsy specimen handling. This has the potential to...
The iViz is a lightweight Point Of Care (POC) ultrasound solution, specifically designed for emerging sub-segments where there is need for a highly accessible and mobile solution that is capable throughout key areas of the patient care path. The iViz...
Better detection. Clinically superior. Low dose.** What if we could find breast cancers earlier? See lesions more clearly? Reduce the number of unnecessary biopsies? Questions like these inspired Hologic researchers and scientists to develop Hologic...
BioZorb® 3D Bioabsorbable Marker The BioZorb® is a 3D implantable marker that consists of a spiral, bioabsorbable framework embedded with 6 permanent, titanium clips designed to precisely mark your surgical excision site. Designed to improve outcomes...